Idt Australia Limited · ASX:IDT
Idt Australia — Investor Presentation (October 2014)
20 slides from Idt Australia's investor presentation, Oct 22, 2014
Slide 1: Good Medicine
GOOD MEDICINE AjUO ssn feuosJec 105
Slide 2: Safe Harbour
SAFE HARBOUR For personal use only This presentation contains forward-looking statements that are subject to risks and uncertainties. Such statements involve known and unknown risks that may cause the actual results, performance or achievements of IDT Australia Ltd to be materially different from th
Slide 3: Making Good Medicine
MAKING For personal use only GOOD MEDICINE We are IDT Australia. Since 1973 we have been developing and manufacturing some of the world’s most vital therapeutics for serious diseases, for most of the world’s leading pharmaceutical firms. We make good medicine. www.idtaus.com.au 02
Slide 4: Who We Manufacture For
For personal use only WHO WE MANUFACTURE FOR
Slide 5: Our Customers Are World Leaders
OUR CUSTOMERS ARE WORLD LEADERS For personal use only www.idtaus.com.au 04
Slide 6: Creating World Leading Products
CREATING WORLD LEADING PRODUCTS For personal use only SENSITIZING DRUGS ANTI–CANCER DRUGS HORMONES CARBOHYDRATE DRUGS HIGH CONTAINMENT TABS/CAPS HIGH CONTAINMENT TAB COATING www.idtaus.com.au 05
Slide 7: That We Make Into Medicines for a Global Market
THAT WE MAKE INTO MEDICINES FOR A GLOBALMARKET For personal use only TEMOZOLOMIDE ACETAZOLAMIDE THIOTEPA THALIDOMIDE MITOXANTRONE ERTAPENEM PENTOSAN www.idtaus.com.au 06
Slide 8: Medicines Made in Our Melbourne Facility
MEDICINES MADE IN OUR MELBOURNE FACILITY For personal use only $75m advanced manufacturing facility 12,000m2 state of the art Currently 10-15% capacity utilization Large scope for growth without need for: major CAPEX; or additional site support costs Ability to manufacture from gram to tonnage scale
Slide 9: Trialed in Our Clinical Unit
TRIALED IN OUR CLINICAL UNIT For personal use only CMAX clinical trials facility; Established 1993; Australia’s oldest, largest & most experienced clinical trials unit; Fifty bed clinical unit located at Royal Adelaide Hospital; Uses services of RAH – Ethics Committee, medical specialists & services
Slide 10: A Prescription for Growth
For personal use only A PRESCRIPTION FOR GROWTH
Slide 11: Move from Making to Marketing
MOVE FROM MAKING TO MARKETING For personal use only www.idtaus.com.au 10
Slide 12: Developing Our Own Speciality Generics
DEVELOPING OUR OWN SPECIALITY GENERICS For personal use only $$ MARGIN WITHIN VALUE CHAIN IDT REGISTRATION & SUPPLY DISTRIBUTOR IDT’s current 2% margin share WHOLESALER Available margin up to 40 -50% Example: PROJECT TETON: IDT currently the dominant supplier of active pharmaceutical ingredients for
Slide 13: Effect of Operational Leverage
EFFECT OF OPEARTIONAL LEVERAGE For personal use only SCENARIO: Organic growth + product registrations + M&A Revenue Growth Rate Profit Growth Rate BREAKEVEN Year 1 Year 2 Year 3 Year 4 www.idtaus.com.au 12
Slide 14: Good Medicine & Higher Returns for IDT
GOOD MEDICINE & HIGHER RETURNS FOR IDT For personal use only SELL MORE EXISTING PRODUCTS EXTRACT MORE PROFITS • High fixes costs = operational leverage. • Extract more profits from those products to improve • As a result, profits will rise faster than revenues past our share of the value chain. brea
Slide 15: Highlights of the Past Year
HIGHLIGHTS OF THE PAST YEAR For personal use only NEW MANAGEMENT TEAM New management team and strengthen board MAJOR RE-POSITIONING TO BOOST REVENUE & MARGINS: Filed first IDT ANDA for temozolomide Temozolomide US distribution deal with milestones/profit split with Mayne Pharma Further projects in d
Slide 16: Board & Management in Place to Deliver
BOARD & For personal use only MANAGEMENT IN PLACE TO DELIVER MANAGEMENT TEAM BOARD Dr Paul D R MacLeman (CEO & MD) Graeme Kaufman (Chairman) Jane Kelly (Clinical) Dr Paul D R MacLeman (MD) Joanna Johnson (CFO) Geoff Lord (Vice Chairman) Stéphane Redey (Manufacturing) Dr Graeme Blackman (NED) Mark Ro
Slide 17: Financially Positioned to Deliver
FINANCIALLY POSITIONED TO DELIVER For personal use only FINANCIALS MARKET CAP $17.0m (16 Oct 14) 2013 2014 REVENUE $13.4m $13.4m EBIT* ($4.4m) ($6.0m) CASH BALANCE $0.6m $2.4m DEBT** $1.9m $0.1m *After one-off charges ** ~$3m unused debt facility available CAPITAL STRUCTURE 77.37M SHARES ON ISSUE 50
Slide 18: Target 2015 Milestones
TARGET For personal use only 2015 MILESTONES INCREASED 2014/15 ORGANIC SALES GROWTH MOVEMENT OF AN ADDITIONAL INTERNAL PRODUCT TOWARDS MARKET ACQUISITION OF APPROVED PRODUCTS FOR MAJOR MARKETS MOVE FROM SERVICE PROVIDER TOWARDS SPECIALTY GENERICS PHARMA COMPANY, GROWTH AND PROFITS www.idtaus.com.au
Slide 19: Contact Us
CONTACT US For personal use only DR PAUL D R MACLEMAN MANAGING DIRECTOR +61 (0) 3 9801 8888 info@idtaus.com.au www.idtaus.com.au Follow Us Twitter @IDTAus www.idtaus.com.au 18
Slide 20: Questions and Answers
For personal use only QUESTIONS AND ANSWERS